Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Solid Biosciences said federal regulators have granted its fast-track designation for the company's investigational gene therapy for the treatment of a heart rhythm condition.

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Curiosity, stress and peer influence are among the main reasons why young Malaysians get involved in substance abuse, says ...